{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:51:58Z","timestamp":1789685518399,"version":"4.0.1"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate switching and discontinuation of biologic disease-modifying antirheumatic drugs (bDMARDs) among psoriatic arthritis (PsA) patients in Japan over 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Claims data from the Japan Medical Data Centre (1\/2005\u201310\/2023) were analysed for patients with a PsA diagnosis on or before first bDMARD claim (index date) and\u2009\u2265\u20096\u00a0months of eligibility pre-index. Treatment switch (claim for another bDMARD) and discontinuation (treatment gap \u2265150% days\u2019 supply of last prescription) were evaluated up to 12\u00a0months post-index. Hazard ratios for switching and discontinuation were estimated using multivariate Cox proportional hazards models adjusted for baseline characteristics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Included patients received adalimumab (n\u00a0=\u2009323), brodalumab (n\u00a0=\u200971), certolizumab pegol (n\u00a0=\u2009162), guselkumab (n\u00a0=\u2009157), ixekizumab (n\u00a0=\u2009239), risankizumab (n\u00a0=\u2009117), secukinumab (n\u00a0=\u2009250), or ustekinumab (n\u00a0=\u200960). At 12\u00a0months, 21.7% switched bDMARDs and 38.1% discontinued their index bDMARD. Risankizumab had the lowest switching rate (18.4%), followed by secukinumab (19.1%) and ixekizumab (19.7%). Risankizumab had the lowest discontinuation rate (23.4%), followed by ustekinumab (27.6%) and ixekizumab (29.7%). Hazard ratios of switching and\/or discontinuation were significantly higher for most bDMARDs (except ixekizumab, ustekinumab) versus risankizumab (P\u00a0&amp;lt;\u2009.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching and discontinuation were common within 1-year of bDMARD treatment for PsA patients in Japan. Risankizumab demonstrated the lowest rates of switching and\/or discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf099","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:07:51Z","timestamp":1763644071000},"page":"430-438","source":"Crossref","is-referenced-by-count":1,"title":["Real-world switching and discontinuation patterns for biologic disease-modifying antirheumatic drugs in patients with active psoriatic arthritis in Japan"],"prefix":"10.1093","volume":"36","author":[{"given":"Mitsumasa","family":"Kishimoto","sequence":"first","affiliation":[{"name":"Department of Nephrology and Rheumatology, Kyorin University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M","family":"Soliman","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Nunag","sequence":"additional","affiliation":[{"name":"Data Analytics & Evidence Generation, Medicus Economics, LLC , Milton, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Lippe","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Patel","sequence":"additional","affiliation":[{"name":"AbbVie Inc. , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Davis","sequence":"additional","affiliation":[{"name":"Data Analytics & Evidence Generation, Medicus Economics, LLC , Milton, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Kameda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"2026041500573331600_ref1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American Dermatology Clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2026041500573331600_ref2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/1346-8138.16423","article-title":"Patient perceptions of psoriatic disease in Japan: results from the Japanese subgroup of the understanding psoriatic disease leveraging insights for treatment (UPLIFT) survey","volume":"49","author":"Torii","year":"2022","journal-title":"J Dermatol"},{"key":"2026041500573331600_ref3","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis","volume-title":"Rheumatology (Oxford)","author":"Lembke"},{"key":"2026041500573331600_ref4","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.141598","article-title":"Prevalence and clinical characteristics of psoriatic arthritis in Japan","volume-title":"Rheumatol","author":"Ohara"},{"key":"2026041500573331600_ref5","doi-asserted-by":"crossref","DOI":"10.1080\/14397595.2021.1886629","article-title":"Treatment practices and costs among patients with psoriatic arthritis: a Japanese hospital claims database analysis","volume-title":"Mod Rheumatol.","author":"Inui"},{"key":"2026041500573331600_ref6","doi-asserted-by":"crossref","DOI":"10.20452\/pamw.16639","article-title":"Recent advances in the management of psoriatic arthritis: practical considerations","volume-title":"Pol Arch Intern Med.","author":"Harrison"},{"key":"2026041500573331600_ref7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/2040622312459673","article-title":"Steps in the management of psoriatic arthritis: a guide for clinicians","volume":"3","author":"Cuchacovich","year":"2012","journal-title":"Ther Adv Chronic Dis"},{"key":"2026041500573331600_ref8","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/1346-8138.16691","article-title":"English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)","volume":"50","author":"Saeki","year":"2023","journal-title":"J Dermatol"},{"key":"2026041500573331600_ref9","doi-asserted-by":"crossref","first-page":"2299598","DOI":"10.1080\/09546634.2023.2299598","article-title":"Real-world biologic treatment patterns and healthcare resource utilization in psoriasis patients using an insurance claims database in Japan","volume":"35","author":"Miyazaki","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"2026041500573331600_ref10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13555-023-01064-1","article-title":"Real-world discontinuation and switching patterns for interleukin-inhibitor treatments in patients with moderate-to-severe psoriasis in Japan","volume":"14","author":"Tada","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026041500573331600_ref11","doi-asserted-by":"crossref","DOI":"10.1111\/1346-8138.16543","article-title":"Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: a retrospective claims database study","volume-title":"J Dermatol","author":"Tada"},{"key":"2026041500573331600_ref12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12895-018-0074-0","article-title":"Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database","volume":"18","author":"Sruamsiri","year":"2018","journal-title":"BMC Dermatol"},{"key":"2026041500573331600_ref13","doi-asserted-by":"crossref","DOI":"10.1159\/000488586","article-title":"Effectiveness end points in real-world studies on biological therapies in psoriasis: systematic review with focus on drug survival","volume-title":"Dermatol","author":"Costanzo"},{"key":"2026041500573331600_ref14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"2026041500573331600_ref15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/1346-8138.17055","article-title":"A cross-sectional questionnaire survey involving physicians for the clarification of the diagnosis and current status of therapeutic intervention of psoriatic arthritis in Japan","volume":"51","author":"Asahina","year":"2024","journal-title":"J Dermatol"},{"key":"2026041500573331600_ref16","volume-title":"Japan: JMDC Claims Database","author":"JMCD"},{"key":"2026041500573331600_ref17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson comorbidity index: a critical review of Clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"key":"2026041500573331600_ref18","doi-asserted-by":"crossref","first-page":"2200869","DOI":"10.1080\/09546634.2023.2200869","article-title":"Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States","volume":"34","author":"Wu","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026041500573331600_ref19","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"2026041500573331600_ref20","first-page":"623","article-title":"Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database","volume":"24","author":"Walsh","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"key":"2026041500573331600_ref21","doi-asserted-by":"crossref","first-page":"e002681","DOI":"10.1136\/rmdopen-2022-002681","article-title":"Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)","volume":"8","author":"Pina Vegas","year":"2022","journal-title":"RMD Open"},{"key":"2026041500573331600_ref22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026041500573331600_ref23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40744-021-00286-z","article-title":"Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis-a retrospective database study","volume":"8","author":"Sewerin","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2026041500573331600_ref24","doi-asserted-by":"crossref","first-page":"1395968","DOI":"10.3389\/fimmu.2024.1395968","article-title":"Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12\/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database","volume":"15","author":"Strunz","year":"2024","journal-title":"Front Immunol"},{"key":"2026041500573331600_ref25","doi-asserted-by":"crossref","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2026041500573331600_ref26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s13555-024-01172-6","article-title":"Treatment discontinuation in patients with psoriasis treated with biologics: a retrospective analysis of German health claims data","volume":"14","author":"Pinter","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026041500573331600_ref27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/1346-8138.14834","article-title":"Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University psoriasis registry","volume":"46","author":"Bayaraa","year":"2019","journal-title":"J Dermatol"},{"key":"2026041500573331600_ref28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1346-8138.15146","article-title":"Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan","volume":"47","author":"Kishimoto","year":"2020","journal-title":"J Dermatol"},{"key":"2026041500573331600_ref29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40744-024-00638-5","article-title":"Efficacy and safety of risankizumab in patients with psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Su","year":"2024","journal-title":"Rheumatol Ther"},{"key":"2026041500573331600_ref30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","article-title":"Treatment persistence of biologics among patients with psoriatic arthritis","volume":"23","author":"Haddad","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2026041500573331600_ref31","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/PPA.S167508","article-title":"Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review","volume":"12","author":"Murage","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2026041500573331600_ref32","doi-asserted-by":"crossref","first-page":"e15067","DOI":"10.1111\/exd.15067","article-title":"Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan","volume":"33","author":"Tada","year":"2024","journal-title":"Exp Dermatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf099\/65550172\/roaf099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/430\/65550172\/roaf099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/430\/65550172\/roaf099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:46Z","timestamp":1776229066000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/430\/8343349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,26]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf099","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,26]]}}}